Mind + Muscle

technical minds + legal muscle


dig deep

Guardians at the Gate: Patent Protection of Therapeutic Monoclonal Antibodies through Product Life Cycle Management (Part 3)

  • 11.01.09
  • Kevin W. McCabe & Paul A. Calvo

Product life cycle management, which necessarily utilizes a multi-disciplinary approach, is an essential tool for companies that develop or market therapeutic monoclonal antibodies (mAbs).  Too little attention to such a plan, or use of the wrong resources, could substantially curtail a product’s life span.  The most difficult part of the therapeutic antibody business is the development of high-quality, safe and effective products.  Great care should thus be taken to ensure that products with these characteristics are positioned in a marketplace that is competition-free for as long as possible.  In an era of mAbs with billion dollar markets, the loss of even a single day of sales could cost companies millions of dollars in lost revenue.

Related People

Related Services

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.